title: The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform.
abstract: The US Tox21 collaborative program represents a paradigm shift in toxicity testing of chemical compounds from traditional in vivo tests to less expensive and higher throughput in vitro methods to prioritize compounds for further study, identify mechanisms of action and ultimately develop predictive models for adverse health effects in humans. The NIH Chemical Genomics Center (NCGC) is an integral component of the Tox21 collaboration owing to its quantitative high-throughput screening (qHTS) paradigm, in which titration-based screening is used to profile hundreds of thousands of compounds per week. Here, we describe the Tox21 collaboration, qHTS-based compound testing and the various Tox21 screening assays that have been validated and tested at the NCGC to date.
authors: NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-3370, USA.
authors: Sunita J
authors: SJ
authors: Shukla
authors: Ruili
authors: R
authors: Huang
authors: Christopher P
authors: CP
authors: Austin
authors: Menghang
authors: M
authors: Xia
mesh_terms: D005544:Forecasting; D057166:High-Throughput Screening Assays / Q000639:trends; D006801:Humans; D018675:Toxicity Tests / Q000379:methods* / Q000639:trends